(Q43211470)

16 November 2017

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results (English)

1 reference

16 November 2017

0 references

G Comi

1

1 reference

16 November 2017

P O'Connor

2

1 reference

16 November 2017

X Montalban

3

1 reference

16 November 2017

J Antel

4

1 reference

16 November 2017

E-W Radue

5

1 reference

16 November 2017

G Karlsson

6

1 reference

16 November 2017

H Pohlmann

7

1 reference

16 November 2017

S Aradhye

8

1 reference

16 November 2017

L Kappos

9

1 reference

16 November 2017

FTY720D2201 Study Group

10

1 reference

16 November 2017

22 December 2009

1 reference

Multiple Sclerosis Journal

16 November 2017

1 reference

16 November 2017

16

1 reference

16 November 2017

2

1 reference

16 November 2017

197-207

1 reference

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

16 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509357065

21 January 2018

Identifiers

DOI

10.1177/1352458509357065

1 reference

16 November 2017

1 reference